Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
The Oncologist|April 5, 2007
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelFrederike K Engels, Floris A de Jong, Alex Sparreboom, et al.
The Prostate|March 22, 2016
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulationEllen de Morrée, Robert van Soest, Ashraf Aghai, et al.
Clinical Pharmacokinetics|October 9, 2015
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI SwitchLisette Binkhorst, Marjolein Bannink, Peter de Bruijn, et al.
Oncotarget|May 3, 2018
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanylEvelien J M Kuip, Wendy H Oldenmenger, Martine F Visser-Thijs, et al.
Pharmaceuticals (Basel, Switzerland)|January 13, 2021
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular CarcinomaKoen G A M Hussaarts, Leni van Doorn, Sander Bins, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
Molecular Pharmacology|June 26, 2015
Lysosomal Sequestration Determines Intracellular Imatinib LevelsHerman Burger, Alexander T den Dekker, Sandra Segeletz, et al.
British Journal of Clinical Pharmacology|June 30, 2015
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanesAnne-Joy M de Graan, Alex Sparreboom, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancerLia van Zuylen, John Bridgewater, Alex Sparreboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumorsDiane A J van der Biessen, Herman Burger, Peter de Bruijn, et al.
Pageof 9